Treatment program for erectile dysfunction in patients with cardiovascular diseases

Area of Science:

• Cardiovascular Medicine
• Urology
• Pharmacology

Background:

• Erectile dysfunction (ED) is a common comorbidity in patients with cardiovascular disease (CVD).
• Managing ED in CVD patients requires careful consideration of treatment safety and efficacy.
• A progressive treatment approach may optimize outcomes for this complex patient population.

Purpose of the Study:

• To evaluate the effectiveness of a stepwise treatment protocol for erectile dysfunction.
• To assess the outcomes in patients with cardiovascular diseases undergoing this progressive ED therapy.
• To determine the success rates of various treatment modalities, including oral medication, intracavernous injections, and penile prosthesis.

Main Methods:

• A cohort of 453 male patients (aged 36-91) with cardiovascular disease and erectile dysfunction were enrolled.
• Treatment initiated with sildenafil citrate, escalating to intracavernous injections (BiMix, TriMix, QuadriMix), combination therapy, or penile prosthesis based on response.
• Patients were followed for 2 years to assess treatment effectiveness and adjust dosages or treatment plans as needed.

Main Results:

• Initial sildenafil citrate treatment yielded positive responses in 49.2% of patients.
• Intracavernous injections showed high success rates: BiMix (54.4%), TriMix (75.2%), and QuadriMix (57.1%).
• Overall, 98.7% achieved sufficient erection for intercourse immediately post-treatment, and 92.2% at 2-year follow-up. Spontaneous erections were achieved by 10.7%.

Conclusions:

• A progressive, stepwise treatment program is highly effective for managing erectile dysfunction in men with cardiovascular disease.
• The treatment algorithm allows for tailored therapeutic escalation, maximizing success rates and patient satisfaction.
• This approach offers a viable and successful management strategy for ED in a high-risk cardiovascular patient group.